Claims for Patent: 7,744,886

Summary for Patent: 7,744,886

Title:	Methods for interfering with rank signaling
Abstract:	Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.
Inventor(s):	Anderson; Dirk M (Port Townsend, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/214,914
Patent Claims:	1. A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling. 2. A method of claim 1, wherein the blocking antibody is a monoclonal antibody. 3. A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a fragment of a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling, wherein the fragment is selected from the group consisting of a) an extracellular domain comprising amino acids 69-317 of SEQ ID NO:13, and b) a receptor binding domain comprising amino acids 162-317 of SEQ ID NO:13. 4. A method of claim 3, wherein the blocking antibody is a monoclonal antibody.

Details for Patent 7,744,886

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2016-12-23
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2016-12-23

International Patent Family for US Patent 7,744,886

Country	Patent Number	Estimated Expiration
Austria	401404
Austria	412746
Austria	497001
Austria	517916
Australia	3988899
Australia	5618098
Australia	5718498